Market Cap | 3.77B | P/E | - | EPS this Y | -151.90% | Ern Qtrly Grth | - |
Income | -137.24M | Forward P/E | -8.01 | EPS next Y | 3.00% | 50D Avg Chg | -8.00% |
Sales | 295.39M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -3.00% |
Dividend | N/A | Price/Book | 3.90 | EPS next 5Y | - | 52W High Chg | -30.00% |
Recommedations | 1.70 | Quick Ratio | 11.37 | Shares Outstanding | 142.61M | 52W Low Chg | 27.00% |
Insider Own | 13.68% | ROA | -8.70% | Shares Float | 123.16M | Beta | 1.39 |
Inst Own | 84.55% | ROE | -11.33% | Shares Shorted/Prior | 10.50M/9.41M | Price | 27.56 |
Gross Margin | -36.12% | Profit Margin | -46.46% | Avg. Volume | 688,159 | Target Price | 39.69 |
Oper. Margin | -70.46% | Earnings Date | Aug 6 | Volume | 498,608 | Change | -2.68% |
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Wedbush | Outperform | May 8, 24 |
Stifel | Hold | May 8, 24 |
HC Wainwright & Co. | Buy | May 8, 24 |
UBS | Buy | Apr 9, 24 |
Goldman Sachs | Buy | Feb 29, 24 |
HC Wainwright & Co. | Buy | Feb 28, 24 |
Wedbush | Outperform | Feb 28, 24 |
HC Wainwright & Co. | Buy | Feb 22, 24 |
Citigroup | Buy | Dec 13, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
SATO VICKI L | Director Director | Jan 16 | Sell | 18.42 | 1,666 | 30,688 | 123,041 | 01/18/24 |
Ho Carole | Chief Medical Office.. Chief Medical Officer | Jan 10 | Sell | 19.02 | 4,668 | 88,785 | 147,794 | 01/12/24 |
Watts Ryan J. | President and CEO President and CEO | Jan 09 | Sell | 19.78 | 7,818 | 154,640 | 2,268,363 | 01/11/24 |
Ho Carole | Chief Medical Office.. Chief Medical Officer | Jan 05 | Sell | 19.43 | 9,972 | 193,756 | 198,777 | 01/09/24 |
Krognes Steve E. | Director Director | Jan 05 | Sell | 19.43 | 3,208 | 62,331 | 142,591 | 01/09/24 |
Schuth Alexander O. | COFO and Secretary COFO and Secretary | Jan 05 | Sell | 19.43 | 9,972 | 193,756 | 539,307 | 01/09/24 |
Watts Ryan J. | President and CEO President and CEO | Jan 05 | Sell | 19.43 | 17,483 | 339,695 | 2,276,181 | 01/09/24 |
SATO VICKI L | Director Director | Dec 15 | Sell | 23.39 | 1,666 | 38,968 | 124,707 | 12/18/23 |
SATO VICKI L | Director Director | Nov 15 | Sell | 19.13 | 1,666 | 31,871 | 126,373 | 11/16/23 |
SATO VICKI L | Director Director | Oct 16 | Sell | 20.66 | 1,666 | 34,420 | 128,039 | 10/18/23 |
Schuth Alexander O. | COFO and Secretary COFO and Secretary | Aug 23 | Sell | 23.17 | 2,522 | 58,435 | 518,989 | 08/25/23 |
Ho Carole | Chief Medical Office.. Chief Medical Officer | Aug 23 | Sell | 23.22 | 2,522 | 58,561 | 182,809 | 08/25/23 |
Krognes Steve E. | Director Director | Aug 21 | Sell | 22.60 | 1,419 | 32,069 | 145,799 | 08/23/23 |
SATO VICKI L | Director Director | Aug 15 | Sell | 24.30 | 1,666 | 40,484 | 131,371 | 08/17/23 |
Ho Carole | Chief Medical Office.. Chief Medical Officer | Aug 14 | Sell | 23.79 | 2,768 | 65,851 | 182,809 | 08/16/23 |
Schuth Alexander O. | COFO and Secretary COFO and Secretary | Aug 14 | Sell | 23.67 | 2,772 | 65,613 | 518,989 | 08/16/23 |
Watts Ryan J. | President and CEO President and CEO | Aug 10 | Sell | 25.03 | 2,526 | 63,226 | 2,239,913 | 08/14/23 |
Watts Ryan J. | President and CEO President and CEO | Aug 10 | Option | 0.68 | 2,526 | 1,718 | 2,242,439 | 08/14/23 |
Ho Carole | Chief Medical Office.. Chief Medical Officer | Aug 10 | Sell | 24.15 | 2,857 | 68,997 | 185,577 | 08/14/23 |
Schuth Alexander O. | COFO and Secretary COFO and Secretary | Aug 10 | Sell | 24.18 | 2,853 | 68,986 | 521,761 | 08/14/23 |
Schuth Alexander O. | COFO and Secretary COFO and Secretary | Jul 17 | Sell | 29.81 | 19,702 | 587,317 | 518,989 | 07/19/23 |
Schuth Alexander O. | COFO and Secretary COFO and Secretary | Jul 17 | Option | 5.28 | 10,000 | 52,800 | 538,691 | 07/19/23 |
SATO VICKI L | Director Director | Jul 17 | Sell | 29.60 | 1,666 | 49,314 | 133,037 | 07/19/23 |
SATO VICKI L | Director Director | Jun 28 | Sell | 29.77 | 1,666 | 49,597 | 134,703 | 06/30/23 |
Watts Ryan J. | President and CEO President and CEO | Apr 20 | Option | 0.68 | 25,000 | 17,000 | 2,264,713 | 04/24/23 |
Watts Ryan J. | President and CEO President and CEO | Apr 20 | Sell | 25.08 | 25,000 | 627,000 | 2,239,913 | 04/24/23 |
Schuth Alexander O. | COFO and Secretary COFO and Secretary | Apr 12 | Sell | 25.04 | 10,000 | 250,400 | 528,691 | 04/14/23 |
Schuth Alexander O. | COFO and Secretary COFO and Secretary | Apr 12 | Option | 5.28 | 10,000 | 52,800 | 533,589 | 04/14/23 |
Krognes Steve E. | Director Director | Feb 13 | Sell | 30.10 | 2,119 | 63,782 | 143,002 | 02/15/23 |
Schuth Alexander O. | COFO and Secretary COFO and Secretary | Feb 13 | Sell | 30.09 | 3,497 | 105,225 | 528,691 | 02/15/23 |
Schuth Alexander O. | COFO and Secretary COFO and Secretary | Feb 13 | Option | 0.68 | 25,000 | 17,000 | 524,902 | 02/15/23 |
Watts Ryan J. | President and CEO President and CEO | Feb 13 | Sell | 30.09 | 33,815 | 1,017,493 | 2,239,913 | 02/15/23 |
Watts Ryan J. | President and CEO President and CEO | Feb 13 | Option | 0.68 | 25,000 | 17,000 | 2,264,913 | 02/15/23 |
Ho Carole | Chief Medical Office.. Chief Medical Officer | Feb 10 | Sell | 29.95 | 3,366 | 100,812 | 184,285 | 02/14/23 |
Watts Ryan J. | President and CEO President and CEO | Feb 09 | Sell | 29.85 | 28,433 | 848,725 | 2,229,031 | 02/13/23 |
Watts Ryan J. | President and CEO President and CEO | Feb 09 | Option | 0.68 | 25,000 | 17,000 | 2,254,031 | 02/13/23 |
Ho Carole | Chief Medical Office.. Chief Medical Officer | Jan 05 | Sell | 28.56 | 4,087 | 116,725 | 178,913 | 01/09/23 |
Krognes Steve E. | Director Director | Jan 05 | Sell | 28.44 | 2,970 | 84,467 | 146,498 | 01/09/23 |
Schuth Alexander O. | COFO and Secretary COFO and Secretary | Jan 05 | Sell | 28.44 | 2,636 | 74,968 | 497,173 | 01/09/23 |
Watts Ryan J. | President and CEO President and CEO | Jan 05 | Sell | 28.44 | 4,800 | 136,512 | 2,223,664 | 01/09/23 |
Ho Carole | Chief Medical Office.. Chief Medical Officer | Jan 03 | Sell | 28.69 | 2,913 | 83,574 | 175,500 | 01/05/23 |
Schuth Alexander O. | COFO and Secretary COFO and Secretary | Jan 03 | Sell | 28.7 | 2,912 | 83,574 | 149,828 | 01/05/23 |
Watts Ryan J. | President and CEO President and CEO | Jan 03 | Sell | 28.73 | 5,029 | 144,483 | 2,213,464 | 01/05/23 |
Tessier-Lavigne Marc | Director Director | Nov 23 | Sell | 30.48 | 20,000 | 609,600 | 1,870,356 | 11/28/22 |
Tessier-Lavigne Marc | Director Director | Sep 28 | Sell | 30.91 | 20,000 | 618,200 | 1,910,356 | 09/30/22 |
Tessier-Lavigne Marc | Director Director | Aug 23 | Sell | 32.02 | 20,000 | 640,400 | 1,930,356 | 08/25/22 |
Ho Carole | Chief Medical Office.. Chief Medical Officer | Aug 23 | Sell | 31.98 | 2,424 | 77,520 | 170,663 | 08/25/22 |
Watts Ryan J. | President and CEO President and CEO | Aug 19 | Sell | 33.22 | 2,404 | 79,861 | 2,202,993 | 08/23/22 |
Krognes Steve E. | Director Director | Aug 19 | Sell | 33.22 | 2,253 | 74,845 | 149,468 | 08/23/22 |
Schuth Alexander O. | COFO and Secretary COFO and Secretary | Aug 19 | Sell | 33.22 | 2,576 | 85,575 | 467,471 | 08/23/22 |